THE PBS listing for medications
containing alendronate has been
extended to include an indication
for reducing fracture risk in patients
with corticosteroid-induced
osteoporosis.
The change applies to Fosamax
Plus D-Cal, Fosamax Plus and
Fosamax, with prolonged use of
corticosteroids being the most
common cause of secondary
osteoporosis.
Alendronate and combination
products are now PBS listed for
patients taking prednisone or
equivalent and doses of 7.5mg/day
or more for more than 3 months -
and no prior fracture is required to
obtain reimbursement.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Nov 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Nov 10
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.